Clinical Trial Update: A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the impact of a supratherapeutic dose of MK-8189 on the QTc interval in participants with schizophrenia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• MK-8189

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Schizophrenia | Phase 1 | Status: COMPLETED | Results posted: 2025-04-22